Addex Therapeutics (ADXN) Cash from Operations (2019 - 2025)

Addex Therapeutics has disclosed Cash from Operations across 7 years of filings, most recently posting 723169897008.2 for Q2 2025.

• Cash from Operations for Q2 2025 came in at 723169897008.2, down 70.2% year-over-year; the trailing twelve-month figure through Jun 2025 was 10608431455.88 (down 100.19% YoY), and the FY2025 annual result was 2618646.08, up 57.31% from the prior year.
• Cash from Operations came in at 723169897008.2 for Q2 2025 at Addex Therapeutics, up from 665911069265.99 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 8307903520167.39 in Q4 2023 to a low of 6175000729211.9 in Q3 2024.
• The 5-year median for Cash from Operations is 3191170.07 (2021), against an average of 1739934186.59.
• Across the five-year window, Cash from Operations soared 260549967.07% in 2023 and sank 98554399.5% in 2024, its largest moves.
• Addex Therapeutics' Cash from Operations stood at 3193736.13 in 2021, then rose by 0.16% to 3188604.01 in 2022, then jumped by 260549967.07% to 8307903520167.39 in 2023, then dropped by 26.49% to 6107133470013.81 in 2024, then tumbled by 88.16% to 723169897008.2 in 2025.
• The last three Cash from Operations figures came in at 723169897008.2 (Q2 2025), 665911069265.99 (Q1 2025), and 6107133470013.81 (Q4 2024), per Business Quant data.